US EditionCould Liquid Biopsy Guide Treatment in Cervical Cancer?
- An exploratory analysis from the global phase 3 CALLA trial found that durvalumab combined with chemoradiotherapy reduced progression risk in locally advanced cervical cancer patients in 2025.
- This investigation used ultrasensitive ctDNA assays to track minimal residual disease and assess progression-free and overall survival outcomes in a randomized, placebo-controlled study.
- Patients with undetectable ctDNA at cycle 6 showed a risk reduction of disease progression or death by at least 95%, and low baseline ctDNA correlated with better survival in both treatment arms.
- The hazard ratio for progression-free survival with undetectable ctDNA in the durvalumab arm was 0.04 , with overall survival benefits similarly significant.
- These results suggest that ctDNA is a sensitive biomarker for predicting outcomes and that durvalumab plus chemoradiotherapy offers meaningful clinical benefit in advanced cervical cancer treatment.
36 Articles
36 Articles
ABC FOX Montana
Akeso's PD-1/CTLA-4 Bispecific Antibody Cadonilimab Approved for First-Line Treatment of Cervical Cancer in All-Comer Populations--Third Approved Indication for Cadonilimab
HONG KONG, June 4, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the National Medical Products Administration (NMPA) has approved the company's first- in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, for the first-line treatment of…
Asturian biopharmaceutical GiStem Research S.L. has announced the official grant by the United States Patent Office (USPTO) of a patent fundamental to its national and international expansion. It is the patent US 12214000B2, entitled Human uterine cervical stem cell population and uses thereof, which protects the use of mesenchymal stem cells of the human cervix (HUCESC) and their secretive for the treatment of multiple diseases.The patent claim…
Coverage Details
Bias Distribution
- 72% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
